Literature DB >> 7686980

Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia.

M J Barry1, A T Cockett, H L Holtgrewe, J D McConnell, S A Sihelnik, H N Winfield.   

Abstract

In previous studies the severity of symptoms of prostatism in men with benign prostatic hyperplasia have not correlated well with prostate size, degree of bladder trabeculation, uroflowmetry or post-void residual volume. As part of a prospective cohort study of benign prostatic hyperplasia treatment effectiveness in 4 university-based urology practices, we correlated symptom severity and these commonly used measures of disease severity. Symptom severity was quantified using the American Urological Association symptom index. Analyses were based on 198 outpatients completing a standardized evaluation (84 of these men have completed 6 months of followup after treatment with prostatectomy, balloon dilation, terazosin or watchful waiting). At baseline, symptom severity was not correlated with uroflowmetry, post-void residual, prostate size and degree of bladder trabeculation. However, symptom severity was much more strongly related to overall health status than the other measures. Reduction in symptoms with treatment did correlate with improvements in uroflowmetry. This poor baseline correlation with symptoms may reflect unreliability in measurement of the physiological/anatomical variables. Alternatively, these parameters may be measuring different pathophysiological phenomena.

Entities:  

Mesh:

Year:  1993        PMID: 7686980     DOI: 10.1016/s0022-5347(17)35482-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  75 in total

1.  The outcomes of outcomes and effectiveness research: impacts and lessons from the first decade.

Authors:  D Stryer; S Tunis; H Hubbard; C Clancy
Journal:  Health Serv Res       Date:  2000-12       Impact factor: 3.402

2.  [Guidelines for German urologists on diagnosis of benign prostate syndrome].

Authors:  R Berges; K Dreikorn; K Höfner; U Jonas; K U Laval; S Madersbacher; M C Michel; R Muschter; M Oelke; L Pientka; C Tschuschke; U Tunn; K Schalkhäuser; B Göckel-Beining; A Heidenreich; H Rübben; K Schalkhäuser; W Thon; J Thüroff; W Weidner
Journal:  Urologe A       Date:  2003-03-12       Impact factor: 0.639

Review 3.  Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.

Authors:  J L Pool; R S Kirby
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 4.  Placebo Medication and Sham Surgery Responses in Benign Prostatic Hyperplasia Treatments: Implications for Clinical Trials.

Authors:  Igor Sorokin; Adam Schatz; Charles Welliver
Journal:  Curr Urol Rep       Date:  2015-10       Impact factor: 3.092

5.  Update on the american urological association guidelines for the treatment of benign prostatic hyperplasia.

Authors:  Steven A Kaplan
Journal:  Rev Urol       Date:  2006

Review 6.  Male overactive bladder: the role of urodynamics and anticholinergics.

Authors:  Scott MacDiarmid; Alexandra Rogers
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

7.  [Benign prostate hyperplasia].

Authors:  U Jonas; A I Gabouev; T R W Herrmann; K Höfner; M C Michel; M Alschibaja; R Hartung
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

8.  The medical therapy of prostatic symptoms study: what will we learn?

Authors:  Kevin M Slawin
Journal:  Rev Urol       Date:  2003

9.  The medical therapy of prostatic symptoms study: what will we learn?

Authors:  Kevin M Slawin
Journal:  Rev Urol       Date:  2003

10.  Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary Incontinence.

Authors:  Lars Viktrup; Beth A. Pangallo; Michael J. Detke; Norman R. Zinner
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.